<DOC>
	<DOCNO>NCT01831076</DOCNO>
	<brief_summary>This phase II trial study well exemestane surgery work treat postmenopausal patient newly diagnose estrogen receptor positive stage II-III breast cancer . Estrogen cause growth breast cancer cell . Hormone therapy use exemestane may fight breast cancer block use estrogen tumor cell .</brief_summary>
	<brief_title>Preoperative Hormone Therapy Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors</brief_title>
	<detailed_description>This study develop preliminary data regard efficacy safety exemestane preoperative treatment postmenopausal woman ER+ PR+ tumor . This trial also design develop predictive model correlate expression know isoforms ER progesterone receptor ( PR ) aromatase enzyme response estrogenic deprivation use exemestane .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer ER positive ( + ) Primary tumor 24 regional lymph node 02 ( T24N02 ) ; patient may metastatic disease , provide localregional surgery clinically indicate Clinical stage II/III Postmenopausal define previous bilateral oophorectomy , woman prior hysterectomy , absence spontaneous menstrual cycle 1 year Newly diagnose Patients prior nonbreast malignancy eligible disease free &gt; = 5 year study entry ; patient squamous basal cell carcinoma skin effectively treat , carcinoma situ cervix treat surgery , lobular carcinoma situ ( LCIS ) ipsilateral contralateral breast treat surgery eligible , even cancer diagnose within 5 year randomization Serum creatinine = &lt; 1.5 x institutional upper limit normal ( ULN ) Hemoglobin within normal limit institution Absolute granulocyte count &gt; = 1500 Platelet count &gt; = 100,000 Serum glutamic oxaloacetic transaminase ( SGOT ) , aspartate aminotransferase ( AST ) serum glutamate pyruvate transaminase ( SGPT ) , alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN Total bilirubin &lt; 2 x ULN institution Alkaline phosphatase &lt; 2 x ULN Completely resect Prior hormone chemotherapy Unable take oral medication Patients nonmalignant systemic disease ( cardiovascular , renal , hepatic , etc . ) would preclude subject protocol therapy</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Tamoxifen</keyword>
</DOC>